A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 130 participants.

Also called NCT01683409

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 130 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01683409
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Japan, Mexico, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01683409. Randomized; double masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2014-09 (actual). Results posted on 2017-07-02.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
Condition
Diabetic Kidney Disease
Intervention (Drug)
Baricitinib
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)
Collaborator
Incyte Corporation (class: industry)

Record details

Record id
cardio:ct-nct01683409
Content hash
fe2b2db1c7ac74440bd9be80738040f0b0c89a474231230f47a6a9b2fec866b9